title: Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report.
abstract: Adverse effects of interferon (IFN) treatment are common, and efforts to minimize these reactions are of considerable importance. IFN-beta-1a is an established therapy for patients with relapsing-remitting multiple sclerosis (MS). Its psychiatric side effects are debated and not yet fully established. The authors report here the case of a patient on IFN-beta-1a therapy for MS who developed acute delirium, delusion, and depression that ceased with treatment discontinuation. Although he had a history of recurrent major depressive disorder, his prior psychiatric illness had followed a course that was clinically independent of other signs of MS. This observation points out psychiatric vulnerability of patients taking IFN-beta-1a therapy for MS and suggests that IFN-beta-1a may induce or exacerbate preexisting psychotic symptoms.
authors.affiliation: Service de psychiatrie, Centre Hospitalier Universitaire, Angers, France. jlgoeb@wanadoo.fr
authors.forename: J L
authors.initials: JL
authors.lastname: Goëb
authors.forename: A
authors.initials: A
authors.lastname: Cailleau
authors.forename: P
authors.initials: P
authors.lastname: Lainé
authors.forename: F
authors.initials: F
authors.lastname: Etcharry-Bouyx
authors.forename: D
authors.initials: D
authors.lastname: Maugin
authors.forename: Ph
authors.initials: P
authors.lastname: Duverger
authors.forename: B
authors.initials: B
authors.lastname: Gohier
authors.forename: K
authors.initials: K
authors.lastname: Rannou-Dubas
authors.forename: F
authors.initials: F
authors.lastname: Dubas
authors.forename: J B
authors.initials: JB
authors.lastname: Garré
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D003693:Delirium / Q000139:chemically induced*; D003702:Delusions / Q000139:chemically induced*; D003863:Depression / Q000139:chemically induced*; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a